Axsome secures top drug’s future with Teva patent settlement

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.

By Ned Pagliarulo • Feb. 10, 2025

Pliant shares collapse as company halts fibrosis drug study

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, but doesn’t yet know what led to their decision.

By Ben Fidler • Feb. 10, 2025

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff.

By BioPharma Dive staff • Feb. 7, 2025

Immune drugmakers Alumis and Acelyrin to merge

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the new company with a bigger cash balance and three drugs in testing.

By Gwendolyn Wu • Feb. 7, 2025

Vertex challenger Sionna prices $191M IPO

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or be used in new, multi-drug combinations.

By Gwendolyn Wu • Feb. 6, 2025

Amgen obesity drug on hold; Regeneron sets first dividend

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.”  

By Ned Pagliarulo • Feb. 5, 2025

Illumina placed on China’s ‘unreliable entity’ list

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s genome sequencing market.

By Susan Kelly • Feb. 5, 2025

Flagship-backed Omega signals it’s headed toward bankruptcy

Flagship’s Pioneering Medicines initiative could acquire Omega’s assets via a stalking horse bid, according to a regulatory filing.

By Gwendolyn Wu • Feb. 4, 2025

Shares of psychedelics biotech nearly double on depression data

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was fast and effective in a treatment-resistant depression trial.

By Jacob Bell • Feb. 3, 2025

Drugmakers prep for bird flu outbreak, despite continued low risk

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak. 

By Kelly Bilodeau • Feb. 3, 2025

Is 2025 the Chinese Year of BioPharma?

China is now a dealmaking hot spot for firms seeking next-generation innovation. What will 2025 hold?

Feb. 3, 2025

A new, non-opioid pain drug is here. Getting it to patients could be agony.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?

By Jacob Bell • Jan. 31, 2025

Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer look in Europe and Daiichi Sankyo is switching CEOs.

By BioPharma Dive staff • Jan. 31, 2025

Metsera, Maze secure combined $415 million in IPOs

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.

By Gwendolyn Wu • Jan. 30, 2025

Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit patients’ ability to access it.

By Jacob Bell • Updated Jan. 30, 2025

23andMe considers a sale as cash runs low

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations and financial commitments.

By Nick Paul Taylor • Jan. 30, 2025

Cargo to drop lead CAR-T therapy, lay off staff after study setback

Safety concerns and disappointing results led Cargo to stop testing the treatment, cut 50% of its workforce and evaluate strategic alternatives.

By Gwendolyn Wu • Jan. 30, 2025

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff. 

By BioPharma Dive staff • Jan. 29, 2025

Atalanta banks $97M to send RNAi drugs into the brain

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat conditions like Huntington’s.

By Gwendolyn Wu • Jan. 28, 2025

Versant invests again in obesity, this time backing Helicore Biopharma

Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant in recent months.

By Jonathan Gardner • Jan. 28, 2025

Sage rebuffs Biogen bid to take it over

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to “maximize” shareholder value.

By Delilah Alvarado • Jan. 27, 2025

The biopharma industry outlook on 2025: Uncertainty and change

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats like competition from China.

By Ned Pagliarulo • Jan. 24, 2025

Mixed results for Keytruda; AbbVie to work with Neomorph

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and the FDA delayed a decision on Stealth’s Barth treatment.

By BioPharma Dive staff • Jan. 24, 2025

Ascentage prices first biotech IPO of 2025, raising $126M

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

By Gwendolyn Wu • Jan. 23, 2025

AI in medtech is taking off. Here are 4 trends to watch in 2025.

New documents clarify how the FDA plans to regulate AI-enabled devices, experts say, but several important questions remain around insurance coverage and generative AI.

By Elise Reuter • Jan. 23, 2025